Disrupted expression of core circadian genes (BMAL1, CLOCK and PER3) and hub genes such as ACTB, GAPDH and CDK1 suggests that circadian gene dysregulation promotes breast cancer progression and represents a potential therapeutic target. This evidence concerns the gene PER3 and breast carcinoma.